How much funding has Ensem Therapeutics raised?

Ensem Therapeutics has raised $77.0M in total funding, most recently a Extension Round.

Who are Ensem Therapeutics's investors?

Ensem Therapeutics's investors include GGV Capital, Legend Star, Pavilion Capital, Cenova Capital, Mitsui & Co, CBC Group.

When was Ensem Therapeutics founded?

Ensem Therapeutics was founded in 2015.

Where is Ensem Therapeutics headquartered?

Ensem Therapeutics is headquartered in Waltham, Massachusetts, United States.

What industry is Ensem Therapeutics in?

Ensem Therapeutics operates in Biotech, Drug Discovery, Oncology.

How many employees does Ensem Therapeutics have?

Ensem Therapeutics has 11-50 employees.

Ensem Therapeutics

Expanding the Universe of Druggable Targets

Waltham, United States · Founded 2015 · $77.0M raised

Biotech

Drug Discovery

Oncology

Headquarters: Waltham, Massachusetts
Employees: 11–50
Founded: 2015
Business Model: B2B

Website: ensemtx.com
Total Funding: $77.0M
Last Round: $10.0M Extension RoundOct 2023
Rounds: 2

About

ENSEM Therapeutics is a preclinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, focused on developing small molecule precision medicines for oncology. The company's proprietary Kinetic Ensemble® platform combines computational AI and deep learning with advanced experimental techniques to identify cryptic binding pockets in traditionally undruggable targets, enabling structure-based drug design against high-value cancer targets. ENSEM's approach captures proteins in motion at ultra-high resolution, uncovering unique therapeutic opportunities that conventional drug discovery methods miss. The company is incubated by CBC Group and serves oncology patients through partnerships with leading research organizations.

Summary

Ensem Therapeutics is a Biotech company based in Waltham, United States, founded in 2015. It has raised $77.0M in total across 2 rounds, most recently a $10.0M Extension Round round in Oct 2023. Investors include GGV Capital, Legend Star and Pavilion Capital.